Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Multicentre, prospective, non-controlled phase II clinical trial to evaluate the efficacy and
tolerability of first line single agent Eribulin in patients with HER2-negative metastatic
breast carcinoma previously exposed to taxanes for early stage.
The primary objective of the study is to determine the median time to progression achieved
with Eribulin. Other secondary objectives will be; overall response rate, clinical benefit
rate, time to treatment progression, duration of response and toxicity profile.